Skip to main content
padlock icon - secure page this page is secure

Identification of Novel Inhibitors for Disrupting EZH2-EED Interactions Involved in Cancer Epigenetics: An In-Silico Approach

Buy Article:

$68.00 + tax (Refund Policy)

Background: The modulation of the chromatin structure and repression of the transcription process has been done by Polycomb Repressive Complex 2 (PRC2) due to trimethylation of LYS27 of histone H3 (H3K27me3). This process is necessary for protein protein interaction (PPI) between EZH2 and EED catalytic subunits. The dysregulation of this complex is responsible for tumorigenesis and progression, making it an important cancer epigenetic therapeutic target. However, until now, there is only one FDA-approved drug called Astemizole has been reported to disrupt interactions between EZH2-EED.

Objective: Identification of novel inhibitors for disrupting EZH2-EED interactions through virtual screening, docking and simulation.

Methodology: In this study, we identified five compounds from in-silico screening & docking studies of a database of ~70000 compounds, which show better binding affinities than Astemizole. These compounds cause destabilization of PRC2 complex by disrupting the interaction between EZH2- EED and which in turn, inhibits its methyltransferase activity in cancerous cells. Molecular Dynamics (MD) Simulation analysis of the best receptor-ligand complex for 50 ns has exhibited that the top-scoring compound captures the expansion of PRC2-driven lymphomas primarily by deregulating PRC2 complex. Further, ADMET properties were analyzed to check their drug like properties.

Results/Conclusion: Our study demonstrates not just the importance of in-silico drug discovery merely but also provides a range of small molecules that can hold the potential to serve as probable lead candidates for disrupting interactions between EZH2-EED. Hence, it has been suggested that the top screened compound C1 can prove to be more potent to inhibit PRC2-driven human cancers.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Docking; EED; EZH2; PPI; PRC2; molecular dynamics

Document Type: Research Article

Publication date: December 1, 2016

More about this publication?
  • Current Proteomics research in the emerging field of proteomics is growing at an extremely rapid rate. The principal aim of Current Proteomics is to publish well-timed review articles in this fast-expanding area on topics relevant and significant to the development of proteomics. Current Proteomics is an essential journal for everyone involved in proteomics and related fields in both academia and industry.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more